Dynamic Advisor Solutions LLC Lowers Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Dynamic Advisor Solutions LLC lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 42.6% during the fourth quarter, HoldingsChannel reports. The firm owned 8,244 shares of the company’s stock after selling 6,123 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in AstraZeneca were worth $540,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in AZN. Martin Investment Management LLC lifted its position in AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after buying an additional 7,615 shares during the period. Nordea Investment Management AB acquired a new stake in shares of AstraZeneca during the 4th quarter worth $754,000. Diversify Wealth Management LLC increased its stake in AstraZeneca by 3.6% during the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after acquiring an additional 153 shares during the last quarter. Ameritas Advisory Services LLC raised its holdings in shares of AstraZeneca by 25.9% in the 4th quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company’s stock worth $622,000 after purchasing an additional 1,949 shares during the period. Finally, Integrated Advisors Network LLC lifted its stake in shares of AstraZeneca by 46.6% in the 3rd quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after purchasing an additional 13,860 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Price Performance

AZN stock opened at $70.08 on Tuesday. The company has a market capitalization of $217.32 billion, a PE ratio of 33.53, a P/E/G ratio of 1.13 and a beta of 0.46. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock’s 50 day moving average is $66.44 and its two-hundred day moving average is $74.14. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.87 earnings per share. Analysts predict that AstraZeneca PLC will post 4.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.